Attenuated Influenza Virions Expressing the SARS-CoV-2 Receptor-Binding Domain Induce Neutralizing Antibodies in Mice

Loes, Andrea N; Gentles, Lauren E.; Greaney, Allison J; Crawford, Katharine H.D.; Bloom, Jesse D.

doi:10.3390/v12090987

Cited by 26 publications

(26 citation statements)

References 56 publications

(82 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, both integrative and non-integrative lentivirus vectors prevented lung deleterious injury in golden hamsters. Another intranasal approach relates to the engineering of an influenza virus-based COVID-19 vaccine expressing a membrane-anchored form of the RBD of the S protein replacing the neuraminidase (NA) gene [ 55 ]. A single intranasal dose of the ΔNA(RBD)-Flu elicited robust neutralizing antibody responses against SARS-CoV-2 at levels comparable to those observed in COVID-19 patients.…”

Section: Preclinical Studiesmentioning

confidence: 99%

Viral Vectors for COVID-19 Vaccine Development

Lundström¹

2021

Viruses

View full text Add to dashboard Cite

Vaccine development against SARS-CoV-2 has been fierce due to the devastating COVID-19 pandemic and has included all potential approaches for providing the global community with safe and efficient vaccine candidates in the shortest possible timeframe. Viral vectors have played a central role especially using adenovirus-based vectors. Additionally, other viral vectors based on vaccinia viruses, measles viruses, rhabdoviruses, influenza viruses and lentiviruses have been subjected to vaccine development. Self-amplifying RNA virus vectors have been utilized for lipid nanoparticle-based delivery of RNA as COVID-19 vaccines. Several adenovirus-based vaccine candidates have elicited strong immune responses in immunized animals and protection against challenges in mice and primates has been achieved. Moreover, adenovirus-based vaccine candidates have been subjected to phase I to III clinical trials. Recently, the simian adenovirus-based ChAdOx1 vector expressing the SARS-CoV-2 S spike protein was approved for use in humans in the UK.

show abstract

Section: Preclinical Studiesmentioning

confidence: 99%

Viral Vectors for COVID-19 Vaccine Development

Lundström¹

2021

Viruses

View full text Add to dashboard Cite

show abstract

“…Influenza virus-based vaccine vectors have the potential to induce cellular and humoral responses both at the mucosal and systemic levels [67,68]. For SARS-CoV-2, it is a clever strategy to associate immunity against the new coronavirus with that of influenza in the same immunization due to the epidemiological and clinical resemblances between coronavirus respiratory diseases and flu.…”

Section: Influenza Virusmentioning

confidence: 99%

“…This could even boost vaccine adherence by the overall population. With such an idea in mind, Loes and collaborators designed and constructed an attenuated influenza A virus expressing the receptor binding domain (RBD) of the spike glycoprotein from SARS-CoV-2 [68]. Preclinical studies in mice showed the production of neutralizing antibodies after a single and low dose [68], opening doors to new possibilities of studies in the area.…”

Section: Influenza Virusmentioning

confidence: 99%

The Rise of Vectored Vaccines: A Legacy of the COVID-19 Global Crisis

Silva

Fonseca

2021

Vaccines

View full text Add to dashboard Cite

The COVID-19 pandemic represents a milestone in vaccine research and development in a global context. A worldwide effort, as never seen before, involved scientists from all over the world in favor of the fast, accurate and precise construction and testing of immunogens against the new coronavirus, SARS-CoV-2. Among all the vaccine strategies put into play for study and validation, those based on recombinant viral vectors gained special attention due to their effectiveness, ease of production and the amplitude of the triggered immune responses. Some of these new vaccines have already been approved for emergency/full use, while others are still in pre- and clinical trials. In this article we will highlight what is behind adeno-associated vectors, such as those presented by the immunogens ChaAdOx1, Sputnik, Convidecia (CanSino, Tianjin, China), and Janssen (Johnson & Johnson, New Jersey, EUA), in addition to other promising platforms such as Vaccinia virus MVA, influenza virus, and measles virus, among others.

show abstract

“…As a surrogate virus model for SARS-CoV-2, we used a Lentivirus bearing a green fluorescent protein (GFP) reporter. It has been known that the spikes of different coronaviruses can be pseudotyped in order to create safer experimental models 40 , 41 . Previous studies showed that HIV-based Lentiviral particles were used as a model in numerous SARS-CoV-2 studies 42 , 43 .…”

Section: Resultsmentioning

confidence: 99%

Integrated photothermal decontamination device for N95 respirators

Muñoz

Comtois-Bona

Cortes

et al. 2021

Sci Rep

View full text Add to dashboard Cite

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for the COVID-19 global pandemic has infected over 25 million people worldwide and resulted in the death of millions. The COVID-19 pandemic has also resulted in a shortage of personal protective equipment (PPE) in many regions around the world, particularly in middle- and low-income countries. The shortages of PPE, such as N95 respirators, is something that will persist until an effective vaccine is made available. Thus, devices that while being easy to operate can also be rapidly deployed in health centers, and long-term residences without the need for major structural overhaul are instrumental to sustainably use N95 respirators. In this report, we present the design and validation of a decontamination device that combines UV-C & B irradiation with mild-temperature treatment. The device can decontaminate up to 20 masks in a cycle of < 30 min. The decontamination process did not damage or reduce the filtering capacity of the masks. Further, the efficacy of the device to eliminate microbes and viruses from the masks was also evaluated. The photothermal treatment of our device was capable of eradicating > 99.9999% of the bacteria and > 99.99% of the virus tested.

show abstract

Attenuated Influenza Virions Expressing the SARS-CoV-2 Receptor-Binding Domain Induce Neutralizing Antibodies in Mice

Cited by 26 publications

References 56 publications

Viral Vectors for COVID-19 Vaccine Development

Viral Vectors for COVID-19 Vaccine Development

The Rise of Vectored Vaccines: A Legacy of the COVID-19 Global Crisis

Integrated photothermal decontamination device for N95 respirators

Contact Info

Product

Resources

About